Media Articles Related to Angiomax (Bivalirudin)
New Guidance on Managing Anticoagulant-Associated ICH
Source: Medscape Medical News Headlines [2015.02.27]
A new study has clinical implications for managing anticoagulant-associated intracerebral hemorrhage in the acute phase and long-term.
Medscape Medical News
Findings may help with the management of anticoagulant-related bleeding within the brain
Source: Blood / Hematology News From Medical News Today [2015.02.26]
Among patients with oral anticoagulation-associated intracerebral hemorrhage (bleeding within the brain), reversal of international normalized ratio (INR; a measure used to determine the clotting...
Anticoagulant fondaparinux associated with lower risk of bleeding and death following heart attack compared to heparin
Source: Blood / Hematology News From Medical News Today [2015.02.18]
Patients who experienced a certain type of heart attack who received the anticoagulant fondaparinux had a lower risk of major bleeding events and death both in the hospital and after six months...
Published Studies Related to Angiomax (Bivalirudin)
The effect of bivalirudin on costs and outcomes of treatment of ST-segment elevation myocardial infarction. [2011.09]
BACKGROUND: Bivalirudin is commonly used during percutaneous coronary intervention (PCI) rather than unfractionated heparin. The higher cost of bivalirudin may be offset if it reduces costly bleeding complications and/or length of stay. We sought to assess the effect of using bivalirudin on the costs of care among patients with ST-segment elevation myocardial infarction (STEMI) undergoing PCI... CONCLUSIONS: Use of bivalirudin among patients with STEMI treated with PCI appears to reduce bleeding and overall costs. Copyright (c) 2011 Mosby, Inc. All rights reserved.
Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. [2011.06.25]
BACKGROUND: Primary results of the HORIZONS-AMI trial have been previously reported. In this final report, we aimed to assess 3-year outcomes... INTERPRETATION: The effectiveness and safety of bivalirudin monotherapy and paclitaxel-eluting stenting are sustained at 3 years for patients with STEMI undergoing primary percutaneous coronary intervention. FUNDING: Boston Scientific and The Medicines Company. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. [2011.06.01]
CONCLUSION: With limited assessment, this direct comparison of high-dose bolus tirofiban versus abciximab produced encouraging results and suggests that further study of this tirofiban dose regimen is warranted. The limited assessments comparing heparin and bivalirudin are consistent with prior observations. Copyright (c) 2010 Wiley-Liss, Inc.
Heparin versus bivalirudin for carotid artery stenting using proximal endovascular clamping for neuroprotection: results from a prospective randomized study. [2010.12]
BACKGROUND: General recommendations indicate that, during a carotid artery stenting (CAS), sufficient unfractionated heparin (UFH) has to be given to maintain the activated clotting time between 250 to 300 seconds. Bivalirudin use is able to reduce postprocedural bleedings in percutaneous interventions when compared with UFH. The study purpose was to evaluate, in a randomized study, the safety and efficacy of bivalirudin versus heparin during CAS, using proximal endovascular occlusion (PEO) as a distal protection device... CONCLUSIONS: The use of bivalirudin should be considered a safe and effective anticoagulation regimen during CAS, using PEO as a distal protection device. Bivalirudin use is associated with a reduced incidence of bleedings. Copyright (c) 2010 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.
A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: The tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. [2010.11.08]
Background: In the absence of high-dose thienopyridines, placebo-controlled trials have demonstrated a reduction in ischemic events with intravenous glycoprotein IIb/IIIa antagonists during percutaneous coronary intervention (PCI)... The limited assessments comparing heparin and bivalirudin are consistent with prior observations.
Clinical Trials Related to Angiomax (Bivalirudin)
Study Of Angiomax In Infants Under Six Months With Thrombosis [Completed]
The goals of this study are:
1. To assess the safety of bivalirudin in infants under six months with arterial or venous
2. To determine the dose of bivalirudin required to achieve adequate anticoagulation as
measured by the activated clotting time (ACT) or activated partial thromboplastin time
(aPTT) in Infants Under Six Months with arterial or venous thrombosis;
3. To determine the outcome of patients on bivalirudin with respect to thrombus resolution
and bleeding complications compared to patients on unfractionated heparin (UH) or low
molecular weight heparin (LMWH).
Antithrombotic Effects of Ticagrelor Versus Clopidogrel [Recruiting]
The purpose of this study is to determine whether treatment with ticagrelor (plus aspirin
and bivalirudin) is more effective than treatment with clopidogrel (plus aspirin and
Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS) [Completed]
The purpose of this study is to show that, when compared with heparin (enoxaparin or
unfractionated heparin) and routine GPIIb/IIIa inhibition (either started upfront or at the
time of percutaneous coronary intervention [PCI]; Arm A):
1. Bivalirudin with routine GPIIb/IIIa inhibition (either started upfront or at the time of
PCI; Arm B) provides non-inferior or superior overall clinical outcomes and
2. Bivalirudin alone (Arm C) reduces clinically significant bleeding. An important
secondary objective for this comparison is to show that bivalirudin is not inferior for
Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention [Recruiting]
The objective of the study is to assess the safety and efficacy of Angiomax® (bivalirudin)
versus unfractionated heparin (UFH) in patients presenting with stable angina or silent
ischemia (positive stress test without chest pain) that undergo percutaneous coronary
The primary endpoint of the study will be major and minor bleeding events, defined by the
REPLACE-2 trial definition, during the index hospitalization and up to 30 days post
The UNBLOCK Study: Utilization of Bivalirudin On Clots in Kids [Recruiting]
Thrombosis is a significant medical complication in children with chronic diseases. The
currently utilized treatments have many drawbacks which can lead to poor outcomes. More
modern therapies are available but have not been systematically tested in children. This
study will determine whether one such medication, bivalirudin is a safer and more effective
This study will monitor what effects the drug has upon the child's body and how the body
processes the study drug (absorption, metabolism and elimination). The study will also
evaluate the drug's effectiveness by following how long it takes to dissolve the clot. The
safety issues being monitored relate to any observations of major or minor bleeding episodes
after taking the drug, and/or any other side effects.
Reports of Suspected Angiomax (Bivalirudin) Side Effects
Thrombosis in Device (18),
OFF Label USE (10),
Coronary Artery Thrombosis (6),
Acute Myocardial Infarction (6),
Myocardial Infarction (6),
Drug Ineffective (4),
Chest Pain (4),
Coronary Artery Occlusion (4),
Procedural Complication (4), more >>